Clinical Trials Logo

Stage IV Colon Cancer clinical trials

View clinical trials related to Stage IV Colon Cancer.

Filter by:

NCT ID: NCT00023933 Completed - Clinical trials for Recurrent Rectal Cancer

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

Start date: October 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer. Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Radiolabeled monoclonal antibody therapy may be effective treatment for colorectal cancer

NCT ID: NCT00019760 Completed - Liver Metastases Clinical Trials

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

Start date: April 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of melphalan given as an isolated hepatic perfusion followed by chemotherapy infused into the liver in patients who have unresectable colorectal cancer that is metastatic to the liver.

NCT ID: NCT00005818 Completed - Clinical trials for Recurrent Rectal Cancer

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

Start date: March 2000
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of combining SU5416 and irinotecan in treating patients who have advanced colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00004074 Completed - Clinical trials for Fallopian Tube Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Start date: August 1999
Phase: Phase 1
Study type: Interventional

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy

NCT ID: NCT00003873 Completed - Clinical trials for Recurrent Rectal Cancer

Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer

Start date: April 1999
Phase: Phase 3
Study type: Interventional

Randomized phase III trial to compare the effectiveness of fluorouracil given by infusion with that of fluorouracil plus eniluracil given by mouth in treating patients who have metastatic, recurrent, or residual advanced colorectal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if fluorouracil is more effective with or without eniluracil for advanced colorectal cancer